Edwards Lifesciences Corporation (EW) Spending and interest coverage
- R&D / revenue · 12 months: Value 16.75%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.58%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 16.75% | Research and development expense / revenue. Period ending 2026-06-30. $1.09B ÷ $6.51B × 100 ≈ 16.75% |
| Stock-based compensation / revenue · 12 months | 2.58% | Share-based compensation / revenue. Period ending 2026-06-30. $168.00M ÷ $6.51B × 100 ≈ 2.58% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.09B USD | Research and Development Expense |
| Revenue | 6.51B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 168.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.45B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.09B | $6.51B | $168.00M | $1.45B | (m) | 16.75% | 2.58% | (m) | (m) |
| 2026-03-31 | $1.09B | $6.30B | $163.30M | $1.35B | (m) | 17.26% | 2.59% | (m) | (m) |
| 2025-12-31 | $1.08B | $6.07B | $158.10M | $1.26B | (m) | 17.79% | 2.61% | (m) | (m) |
| 2025-09-30 | $1.08B | $5.88B | $150.60M | $1.43B | (m) | 18.40% | 2.56% | (m) | (m) |
| 2025-06-30 | $1.06B | $5.69B | $151.50M | $1.47B | (m) | 18.56% | 2.66% | (m) | (m) |
| 2025-03-31 | $1.05B | $5.52B | $157.90M | $1.42B | (m) | 19.03% | 2.86% | (m) | (m) |
| 2024-12-31 | $1.05B | $5.44B | $162.30M | $1.38B | (m) | 19.36% | 2.98% | (m) | (m) |
| 2024-09-30 | $1.13B | $6.31B | $161.10M | $1.64B | (m) | 17.94% | 2.55% | (m) | (m) |
| 2024-06-30 | $1.12B | $6.20B | $151.60M | $1.65B | (m) | 18.11% | 2.44% | (m) | (m) |
| 2024-03-31 | $1.10B | $6.14B | $145.10M | $1.53B | (m) | 17.84% | 2.36% | (m) | (m) |
| 2023-12-31 | $1.07B | $6.00B | $139.40M | $1.53B | $17.60M | 17.85% | 2.32% | 87.16× | Reported |
| 2023-09-30 | $1.03B | $5.82B | $136.80M | $1.58B | (m) | 17.77% | 2.35% | (m) | (m) |
| 2023-06-30 | $997.30M | $5.66B | $134.50M | $1.57B | (m) | 17.63% | 2.38% | (m) | (m) |
| 2023-03-31 | $977.80M | $5.50B | $133.30M | $1.70B | (m) | 17.78% | 2.42% | (m) | (m) |
| 2022-12-31 | $945.20M | $5.38B | $126.80M | $1.75B | $19.20M | 17.56% | 2.36% | 91.07× | Reported |
| 2022-09-30 | $945.80M | $5.36B | $123.10M | $1.68B | (m) | 17.63% | 2.30% | (m) | (m) |
| 2022-06-30 | $950.20M | $5.36B | $119.40M | $1.66B | (m) | 17.74% | 2.23% | (m) | (m) |
| 2022-03-31 | $924.70M | $5.36B | $113.50M | $1.75B | (m) | 17.26% | 2.12% | (m) | (m) |
| 2021-12-31 | $903.10M | $5.23B | $109.30M | $1.69B | $18.40M | 17.26% | 2.09% | 91.86× | Reported |
| 2021-09-30 | $866.00M | $5.09B | $106.00M | $1.67B | (m) | 17.00% | 2.08% | (m) | (m) |
| 2021-06-30 | $823.50M | $4.93B | $102.40M | $1.63B | (m) | 16.72% | 2.08% | (m) | (m) |
| 2021-03-31 | $780.30M | $4.47B | $96.90M | $923.00M | (m) | 17.44% | 2.17% | (m) | (m) |
| 2020-12-31 | $760.70M | $4.39B | $92.60M | $897.60M | $15.80M | 17.34% | 2.11% | 56.81× | Reported |
| 2020-09-30 | $758.90M | $4.37B | $90.10M | $857.00M | (m) | 17.37% | 2.06% | (m) | (m) |
| 2020-06-30 | $758.90M | $4.32B | $86.90M | $793.50M | (m) | 17.56% | 2.01% | (m) | (m) |
| 2020-03-31 | $768.70M | $4.48B | $84.40M | $1.23B | (m) | 17.14% | 1.88% | (m) | (m) |
| 2019-12-31 | $752.70M | $4.35B | $81.30M | $1.15B | $20.70M | 17.31% | 1.87% | 55.40× | Reported |
| 2019-09-30 | $721.90M | $4.15B | $78.90M | $830.70M | (m) | 17.39% | 1.90% | (m) | (m) |
| 2019-06-30 | $688.20M | $3.96B | $76.50M | $785.30M | (m) | 17.36% | 1.93% | (m) | (m) |
| 2019-03-31 | $650.40M | $3.82B | $73.40M | $769.90M | (m) | 17.02% | 1.92% | (m) | (m) |
| 2018-12-31 | $622.20M | $3.72B | $71.00M | $748.20M | $29.90M | 16.71% | 1.91% | 25.02× | Reported |
| 2018-09-30 | $605.70M | $3.63B | $70.30M | (m) | (m) | 16.67% | 1.93% | (m) | (m) |
| 2018-06-30 | $586.80M | $3.55B | $68.70M | (m) | $20.20M | 16.54% | 1.94% | (m) | Reported |
| 2018-03-31 | $567.10M | $3.45B | $64.80M | (m) | (m) | 16.45% | 1.88% | (m) | (m) |
| 2017-12-31 | $552.60M | $3.44B | $61.60M | (m) | $23.20M | 16.09% | 1.79% | (m) | Reported |
| 2017-09-30 | $522.00M | $3.31B | $60.20M | (m) | $16.20M | 15.75% | 1.82% | (m) | Reported |
| 2017-06-30 | $492.10M | $3.23B | $58.80M | (m) | $18.20M | 15.22% | 1.82% | (m) | Reported |
| 2017-03-31 | $470.20M | $3.15B | $57.80M | (m) | $19.20M | 14.93% | 1.83% | (m) | Reported |
| 2016-12-31 | $443.30M | $2.96B | $56.90M | (m) | $19.20M | 14.96% | 1.92% | (m) | Reported |
| 2016-09-30 | $426.60M | $2.87B | $55.90M | (m) | (m) | 14.88% | 1.95% | (m) | (m) |
| 2016-06-30 | $414.50M | $2.74B | $54.10M | (m) | (m) | 15.11% | 1.97% | (m) | (m) |
| 2016-03-31 | $399.10M | $2.60B | $50.60M | (m) | (m) | 15.35% | 1.95% | (m) | (m) |
| 2015-12-31 | $383.10M | $2.49B | $49.90M | (m) | $17.20M | 15.36% | 2.00% | (m) | Reported |
| 2015-09-30 | $368.90M | $2.44B | $49.20M | (m) | (m) | 15.12% | 2.02% | (m) | (m) |
| 2015-06-30 | $355.50M | $2.43B | $48.80M | (m) | (m) | 14.61% | 2.01% | (m) | (m) |
| 2015-03-31 | $347.10M | $2.39B | $49.90M | (m) | (m) | 14.52% | 2.09% | (m) | (m) |
| 2014-12-31 | $346.50M | $2.32B | $48.30M | (m) | $17.20M | 14.92% | 2.08% | (m) | Reported |
| 2014-09-30 | $341.10M | $2.24B | $47.60M | (m) | (m) | 15.22% | 2.12% | (m) | (m) |
| 2014-06-30 | $337.60M | $2.13B | $47.30M | (m) | (m) | 15.86% | 2.22% | (m) | (m) |
| 2014-03-31 | $329.00M | $2.07B | $48.20M | (m) | (m) | 15.88% | 2.33% | (m) | (m) |
| 2013-12-31 | $323.00M | $2.05B | $47.40M | (m) | $9.80M | 15.79% | 2.32% | (m) | Reported |
| 2013-09-30 | $319.30M | $2.02B | $46.70M | (m) | (m) | 15.81% | 2.31% | (m) | (m) |
| 2013-06-30 | $309.00M | $1.97B | $45.70M | (m) | (m) | 15.67% | 2.32% | (m) | (m) |
| 2013-03-31 | $302.50M | $1.94B | $44.10M | (m) | (m) | 15.62% | 2.28% | (m) | (m) |
| 2012-12-31 | $291.30M | $1.90B | $42.10M | (m) | $4.40M | 15.33% | 2.22% | (m) | Reported |
| 2012-09-30 | $277.10M | $1.82B | $40.30M | (m) | (m) | 15.23% | 2.22% | (m) | (m) |
| 2012-06-30 | $265.00M | $1.78B | $39.90M | (m) | (m) | 14.85% | 2.24% | (m) | (m) |
| 2012-03-31 | $255.90M | $1.73B | $36.50M | (m) | (m) | 14.76% | 2.11% | (m) | (m) |
| 2011-12-31 | $246.30M | $1.68B | $35.00M | (m) | $3.10M | 14.67% | 2.09% | (m) | Reported |
| 2011-09-30 | $241.50M | $1.64B | $32.90M | (m) | (m) | 14.72% | 2.01% | (m) | (m) |
| 2011-06-30 | $232.50M | $1.58B | $31.00M | (m) | (m) | 14.74% | 1.97% | (m) | (m) |
| 2011-03-31 | $218.20M | $1.51B | $29.50M | (m) | (m) | 14.44% | 1.95% | (m) | (m) |
| 2010-12-31 | $204.40M | $1.45B | $29.30M | (m) | $2.40M | 14.13% | 2.02% | (m) | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | $1.35B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $175.50M | $1.32B | $28.30M | (m) | $2.70M | 13.28% | 2.14% | (m) | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $139.20M | $1.24B | $28.70M | (m) | $7.20M | 11.25% | 2.32% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |